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Background: Castleman’s disease is a rare and poorly understood disease entity that may resemble more common
conditions and represents a clinical challenge to the treating surgeon.
Case presentation: In this report, we describe a case of a 61-year-old Caucasian woman with a symptomatic
retroperitoneal mass. The specimen obtained from her resection contained a protuberant encapsulated mass,
exhibiting microscopic features consistent with localized, unicentric Castleman’s disease. These characteristics
included architectural features and immunohistochemical findings consistent with the hyaline vascular variant of
Castleman’s disease.
Conclusion: We report a very rare case of a retroperitoneal hyaline vascular type of Castleman’s disease. We discuss
the diagnostic dilemma Castleman’s disease may present to the surgeon, with an emphasis on multidisciplinary
management of these patients. We also review current data on pathogenesis, treatment and outcomes.
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Angiofollicular lymph node hyperplasia, or Castleman’s
disease (CD), is a rare neoplastic disease first identified
in 1956 by Castleman and colleagues [1]. It has been de-
scribed mainly in case reports and small series, thus the
incidence and prevalence of CD are difficult to ascertain.
CD is characterized by massive growth of nonclonal
lymphoid tissue and has been categorized according to
anatomic location, histological presentation and centri-
city (local vs. multicentric). In 65% to 80% of cases, CD
is primarily found in the mediastinum, with an increas-
ing incidence noted in the head and neck region. Mesen-
teric, retroperitoneal and pelvic tumors are unique and
discovered less frequently [2-4]. Clinical imaging cannot
readily distinguish CD from other neoplastic diseases.
Published reports have described CD mimicking lymph-
oma, carcinoma and sarcoma in various anatomic sites,
such as the pancreas, liver and spinal cord [5-7].
The classic histological subtype of CD, representing
76% to 91% of localized disease, is the hyaline-vascular* Correspondence: wilbur.bowne@drexelmed.edu
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reproduction in any medium, provided the ortype (HV-CD). The plasma cell variant (PC-CD) has been
identified in 9% to 24% of CD cases, and a rare hyaline-
vascular plasma cell (or mixed) subtype has also been re-
ported [2,8,9]. Clinically, HV-CD is most often found in
indolent unicentric CD tumors (UCDs), and a more gene-
ralized (multicentric) lymphadenopathy, which frequently
presents with constitutional symptoms, is associated with
PC-CD [2,10].
CD has an unclear etiology, although human herpes
virus 8 (HHV-8) and HIV coinfection has been implicated
in the etiology of multicentric disease (MCD). Although it
has been hypothesized that treatment with highly active
antiretroviral therapies might decrease the incidence of
MCD, MCD has actually increased and further study elu-
cidating the effects of viral seropositivity on dysregulation
of the immune system is ongoing [11]. Additionally, the
roles of autoimmune diseases and Epstein-Barr virus
(EBV) infection in the pathogenesis of CD are now being
explored [12,13].
Historically, the treatment and prognosis of CD are
based on the centricity of the disease rather than on the
histopathology. Surgical resection of UCDs can be cura-
tive, with long-term, recurrence-free survival described
in the majority of case reports and series. The tumor’sl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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important factors in predicting surgical morbidity [2,14].
MCD, however, often presents additional diagnostic un-
certainty and treatment challenges. Immunotherapy, che-
motherapy and antiviral therapy are the mainstays of
treatment. Surgical treatment is reserved for either exci-
sional biopsy, debulking of a dominant disease focus or
palliative resection [14,15]. Transformation into non-
Hodgkin’s lymphoma may occur, and, despite treatment,
mortality due to MCD occurs in 40% of patients within 10
years from the time of diagnosis [14].
In the present report, we describe a rare case of retro-
peritoneal UCD and discuss a multidisciplinary approach
to diagnosis and treatment of patients with this rare cli-
nical entity.
Case presentation
A 61-year-old Caucasian woman was seen by her pri-
mary care physician for a palpable abdominal mass
that had been present for 1½ years. She did not com-
plain of systemic symptoms, general malaise, weight loss,
flank pain or urinary symptoms, but described mild diar-
rhea and right periumbilical pain that radiated to the
right lower quadrant. Her medical history included well-
controlled hypertension and type 2 diabetes mellitus. Her
previous colonoscopic and endoscopic evaluations were
normal. During her physical examination, a nontender,
immobile mass was palpable in the right lower quadrant
without peripheral lymphadenopathy. Examination and la-
boratory studies were otherwise unremarkable. Computed
tomography (CT) with intravenous and oral contrast of
the abdomen and pelvis revealed a heterogeneously en-
hancing, 10.2 × 6.9 × 6.3–cm solid mass in the right retro-
peritoneal space immediately lateral to and displacing the
inferior vena cava and right iliac vasculature (Figure 1AA B 
Figure 1 Preoperative imaging. (A) and (B) Axial and coronal computed
showing a large, heterogeneously enhancing retroperitoneal mass deformiand 1B). Significant deformation of adjacent retroperiton-
eal structures was also observed. There was no evidence
of abdominopelvic adenopathy or intraperitoneal disease.
A biopsy was not performed.
An exploratory laparotomy revealed a large mass with
remarkable tumor and perivascular inflammatory chan-
ges extending to the right iliac vessels and over the infer-
ior vena cava. The mass was completely resected without
the need for multiorgan resection. The blood loss during
surgery was approximately 1 L. The patient underwent
a complete curative resection. She recovered well follo-
wing the operation and was discharged on the seventh
postoperative day. The patient has remained without ra-
diologic evidence of disease recurrence during 2 years
of follow-up.
Pathological findings
A soft encapsulated mass measuring 11.5 × 6.0 × 5.0 cm
with tannish orange cut surfaces was identified in a sur-
gical tissue specimen that had attached fatty and inflam-
matory soft tissue (Figure 2). All surgical margins were
clear, with the closest approximately 2.0 cm from the la-
teral aspect of the inferior vena cava.
Under the microscope, we could see that the nodule
consisted of lymphocytes with marked vascular prolifera-
tion and prominent hyalinization. Low- and high-power
histopathology revealed regressively transformed germi-
nal centers with normal B-cell distribution surrounded
by hypervascular mantle zones composed predominantly
of concentric rings (“onion-skinning”) of small cluster
of differentiation 4 (CD4)-positive T lymphocytes and
plasma cells (Figures 3 and 4). We frequently observed
hyalinized blood vessels perforating the follicles from
the mantle zone. Immunostaining for CD21 demons-
trated the characteristic follicular dendritic network oftomographic scans, respectively, with oral and intravenous contrast
ng the inferior vena cava at the level of the right renal vein (arrow).
Figure 2 Gross specimen. The resected specimen surfaces weighed 340 g and measured 18 × 11 × 7 cm. The tissue specimen contained an
encapsulated mass that measured 11.5 × 6.0 × 5.0 cm and a medial border 2.0 cm from the border of the inferior vena cava.
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positive in some of the transformed germinal centers.
PCR analysis of paraffin-embedded tissue targeting the
T-cell receptor γ gene revealed no gene rearrangement.
In situ hybridization for EBV and immunostaining for
HHV-8 were both negative. These architectural fea-
tures and immunochemical findings are consistent with
HV-CD.Figure 3 Histopathology. Microscopy of resected section showing two a
and eosin stain; original magnification 4×).Discussion
Our patient presented to our institution with a rare,
symptomatic, retroperitoneal, unicentric HV-CD tumor.
Although etiologic factors continue to be elucidated [7],
a major clinical challenge rests first on establishing the
diagnosis of CD. An important initial step is a high cli-
nical index of suspicion for CD in symptomatic patients
[2]. Regardless of whether it presents as an incidentaltrophic, hyalinized germinal centers (two-headed arrow) (hematoxylin
Figure 4 Histopathology. Microscopy of a section taken from the mass exhibiting the hyaline vascular features of Castleman’s disease, including
a characteristic endothelium-lined blood vessel radially penetrating an atrophic germinal center (arrow) (hematoxylin and eosin stain; original
magnification, 20×).
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within differential diagnoses. Multidisciplinary review is
highly recommended and may provide important insight
into establishing the diagnosis of CD.
Primary retroperitoneal tumors are particularly difficult
to diagnose because of their location and often are clini-
cally detected only after the tumor reaches a size that is
large enough to be found with a resultant mass effect andFigure 5 Histological image with immunostaining for cluster of differ
residual germinal centers (arrow) (original magnification, 4×).involvement of surrounding structures. Among primary
retroperitoneal tumors, one-third are sarcomas [16]. Lipo-
sarcomas comprise 70% of retroperitoneal sarcomas and
can often be differentiated on cross-sectional imaging on
the basis of fat distribution [17]. Lymphomas, carcinomas
and neuroendocrine tumors, as well as extragonadal germ
cell tumors, and metastatic melanomas, also occur in the
retroperitoneumentiation 21 antibody. highlights the follicular dendritic network of
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operatively remains controversial. At our institution, if a
mass is suspected to be malignant and appears amenable
to complete surgical resection, we frequently recom-
mend surgical management without preoperative biopsy.
Most surgeons agree that surgical resection in the ap-
propriate clinical setting without biopsy is acceptable
[18]. Biopsy is useful, however, in cases where radiology
is inconclusive or tissue diagnosis prior to surgery may
alter subsequent management [19]. Biopsy is also reaso-
nable in patients whose performance status may preclude
safe surgical resection, thus necessitating alternative ther-
apies or treatment approaches. CT- or ultrasound-guided
percutaneous biopsy is frequently used, and biopsy by
endoscopic ultrasound has proven efficacious for retro-
peritoneal masses adjacent to the bowel [20]. Core-needle
biopsy is often preferable to fine-needle aspiration to ob-
tain appropriate specimens for pathologic evaluation, to
differentiate variant histologic subtypes of mesenchymal
tumors and to distinguish other types of tumors found
within the retroperitoneum [21]. Furthermore, evaluation
of rare clinical entities such as CD requires histologic ar-
chitectural preservation provided by substantial tissue bi-
opsies to render an accurate diagnosis.
An important clinical consideration in CD tumors is
the degree of vascularity, which is more prominent in
the HV-CD variant than in the PC-CD type. The degree
of vascularity is relevant to both the diagnosis and treat-
ment of CD. When CD presents in a rare location (for
example, the head of the pancreas), the increased vascu-
larity may confound the diagnosis and cause suspicion
for primary malignancy with associated angiogenesis
[22]. Zheng et al. [23] described characteristic findings
of CD on CT scans, such as the degree of rim enhance-
ment, that can assist in distinguishing CD from primary
malignancy. Care must also be taken to differentiate UCD
from MCD by using radiologic techniques, as treatment
for these variants differs significantly. At our institution,
we routinely employ dedicated 256 × 256 matrix multide-
tector CT cross-sectional imaging with arterial and venous
phases for diagnostic and preoperative planning. Surgical
resection of highly vascular tumors is technically challen-
ging and is associated with morbidity and possible morta-
lity related to blood loss. Recently published case reports
have described the utilization of preoperative angiography
and embolization to decrease intraoperative bleeding and
subsequent morbidity [24-26].
Once the diagnosis or real clinical suspicion of UCD
has been established, complete surgical resection is the
treatment of choice on the basis of its reported long-
term, recurrence-free survival rate with possible cure
[2,14]. Importantly, surgical resection of large vascular
tumors may be technically challenging, especially in the
mediastinum and retroperitoneum, where vital structurestend to be involved with the tumor itself or with associ-
ated surrounding inflammatory and/or desmoplastic di-
sease response. In many cases, resultant compression of
vital structures due to mass effects necessitates the need
to remove these lesions. Novel neoadjuvant approaches
to facilitate safe surgical resection have been proposed.
Bandera et al. [27] reported the successful use of rituxi-
mab (an anti-CD20 monoclonal antibody) in the neoadju-
vant setting of mediastinal UCD involving the pulmonary
artery and superior vena cava, followed by successful sur-
gical resection. de Vries et al. [28] described the effica-
cious use of neoadjuvant radiotherapy for an unresectable
abdominal UCD involving the iliac vessels to downsize the
tumor, followed by complete surgical resection. In ad-
dition, a limited number of reports have addressed the
response of CD to radiotherapy (2,700 to 4,500 cGy) ad-
ministered to involved sites, with resultant remission of
disease in isolated cases, suggesting a possible role for
radiotherapy in a neoadjuvant or adjuvant setting [29-32].
Our present case report demonstrates the association of a
CD-HV-type tumor with the inferior vena cava and in
close proximity to the iliac vessels, which we treated with
a technically challenging complete surgical resection.
More investigation is required to further evaluate the util-
ity of neoadjuvant strategies with the potential to reduce
the size of tumors in cases where surgery may present a
significant risk to the patient. In certain cases, if complete
resection is not possible, partial resection or observation
with long-term follow-up may be useful. Appropriate
follow-up after surgical resection for the CD-HV type has
not been established. We recommend routine CT yearly
for the first 3 years and again at 5 years postoperatively.
Thereafter follow-up imaging should be clinically driven
based upon suspicion for disease recurrence.
Although the decision-making regarding of UCD and
its management is challenging, MCD presents an even
greater problem for the treating physician and surgeon.
The use of antiviral and antiretroviral therapies is con-
sidered necessary with the addition of chemotherapeutic
agents, including regimens developed for treatment of
lymphoma and rituximab alone, which have demonstrated
variable responses [15]. Despite aggressive medical man-
agement, the rates of relapse, malignant transformation
and disease-related mortality remain high.
Conclusion
In this case report, we describe a rare case of retroperi-
toneal unicentric HV-CD, a poorly understood disease
that creates a diagnostic and therapeutic dilemma for
surgeons. To date, the use of improved radiologic cri-
teria for diagnosis, interventional techniques and opera-
tive, neoadjuvant and adjuvant strategies appear to play
an increasingly important role in the diagnosis and ma-
nagement of patients with this rare disease. Because of
Williams et al. World Journal of Surgical Oncology 2014, 12:30 Page 6 of 7
http://www.wjso.com/content/12/1/30the rarity of CD, the opportunity for clinical trials to
produce uniform evidence-based approaches is unlikely.
With regard to the treatment options for patients with
these rare tumors, we encourage a collaborative, multi-
disciplinary approach that includes surgical specialists,
radiologists, pathologists and oncologists to discuss treat-
ment options to optimize patient outcomes.
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